Working… Menu
Trial record 51 of 372 for:    LENALIDOMIDE AND Dexamethasone

Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma (DSM XIII)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01090089
Recruitment Status : Recruiting
First Posted : March 19, 2010
Last Update Posted : September 8, 2017
ClinAssess GmbH
Information provided by (Responsible Party):
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH

Brief Summary:
In this study for elderly myeloma patients lenalidomide plus low-dose dexamethasone until progression is being compared with age-adjusted tandem high-dose melphalan 140 mg/m² augmented by induction with 3 cycles of lenalidomide plus low-dose dexamethasone before transplantation and lenalidomide maintenance after transplantation.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Lenalidomide, Dexamethasone Drug: Lenalidomide, Dexamethasone, PBSCT Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 348 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Combination of Lenalidomide and Dexamethasone With or Without Intensification by High-dose Melphalan in the Treatment of Multiple Myeloma
Actual Study Start Date : March 1, 2010
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : January 2020

Arm Intervention/treatment
Experimental: Lenalidomid, PBSCT
A1 Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)
Drug: Lenalidomide, Dexamethasone, PBSCT
Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
Other Name: Revlimid

Active Comparator: Lenalidomid
A2 Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
Drug: Lenalidomide, Dexamethasone
Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)
Other Name: Revlimid

Primary Outcome Measures :
  1. Progression-free survival (PFS) [ Time Frame: 5 yrs ]
    To compare the efficacy of both treatment regimens with regard to progression-free survival.

Secondary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: 5 yrs ]
    To assess the safety and overall survival of both treatment regimens.

  2. • Response (complete response [CR], stringent complete response [sCR], very good partial response [VGPR], partial response [PR] and overall response [CR (incl. sCR)+ VGPR + PR]) according to IMWG criteria [ Time Frame: 5 yrs ]
    To investigate other efficacy parameters of both treatment regimens

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   60 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

1. Understand and voluntarily sign an informed consent form. 2. Age 60-75 years at the time of signing the informed consent form. 3. Able to adhere to the study visit schedule and other protocol requirements. 4. Symptomatic MM requiring therapy. 5. Measurable monoclonal protein in serum and/or urine 6. Monoclonal plasma cells in the bone marrow >/= 10% and/or biopsy-proven plasmacytoma 7. Myeloma-related organ dysfunction, at least one of [C] Calcium elevation in the serum (> 11.5 mg/dL or > 2.65 mmol/l) [R] Renal insufficiency (creatinine > 173 μmol/l or > 2 mg/dL) [A] Anemia (Hb < 10 g/dL or 2 g/dL < normal) [B] Bone lesions or general osteoporosis 8. ECOG PS of </= 2 ... 9. Laboratory test results within these ranges within 1 week prior to randomization:

  • ANC >/= 1.0 x 109/L.
  • Platelet count >/= 75 x 109/L or in case of bone marrow infiltration with myeloma cells >/= 30 x 109/L.
  • Total bilirubin </= 2 mg/dL.
  • AST (SGOT) and ALT (SGPT) </= 3 x ULN. 8. Female subjects of childbearing potential must: o Understand the study drug is expected to have a teratogenic risk

    o Agree to use, ..., effective contraception without interruption,...

    o Understand that even if she has amenorrhea, she must follow all the advice on effective contraception.

    o She understands the potential consequences of pregnancy and the need to rapidly consult if there is a risk of pregnancy

    o Agree to have a medically supervised pregnancy test ...

  • Male subjects must

    o Agree to use condoms throughout study drug therapy, during any dose interruption and for one week after cessation of study drug therapy ...

    • Agree not to donate semen during study drug therapy and for one week after end of study drug therapy.
  • All subjects must

    • Agree to abstain from donating blood while taking study drug therapy and for one week following discontinuation of study drug therapy.
    • Agree not to share study drug with another person and to return all unused study drug to the investigator.

      9. Disease free of prior malignancies for >/= 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast.

      10. Able to receive antithrombotic prophylaxis (...). 11. Life-expectancy > 3 months.

Exclusion Criteria:

  1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the ICF.
  2. Pregnant or lactating females
  3. Any condition, incl. the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  4. Patient currently is enrolled in another clinical research study or has been enrolled ...within 4 weeks before randomization and/or is receiving an investigational agent for any reason ...
  5. Known hypersensitivity to thalidomide, dexamethasone, or melphalan.
  6. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
  7. Any prior use of lenalidomide.
  8. Concurrent use of other anti-cancer agents or treatments.
  9. Known positive for HIV or active infectious hepatitis, type A, B or C or treponema pallidum
  10. Prior treatment with dexamethasone discontinued because of ≥ grade 3 dexamethasone-related toxicity.
  11. Any prior chemotherapy with the exception of a short course of dexamethasone more than 4 weeks before randomization.
  12. Immunotherapy or antibody therapy within 8 weeks before randomization.
  13. Major surgery within 4 weeks before randomization.
  14. Renal failure requiring dialysis.
  15. Myocardial infarction within 6 months before randomization, NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
  16. Severe pulmonary disease (diffusion capacity < 60% of normal).
  17. Treatment for cancer other than MM within 5 years before randomization, with the exception of basal cell carcinoma or cervical cancer in situ.
  18. Cardiac amyloidosis.
  19. Poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to the protocol.
  20. Any systemic infection requiring treatment.
  21. Unability or unwillingness of the patient to receive antithrombotic prophylaxis.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01090089

Layout table for location contacts
Contact: Christian Straka +49-8151-17 806

Layout table for location information
Universitätsklinikum Münster Recruiting
Muenster, North Rhein Westfallen, Germany, 48149
Contact: Martin Kropff, PD Dr. med.    0251-8347590   
Universitätsklinikum Aachen Recruiting
Aachen, Germany, 52074
Contact: Tim H. Brümmendorf, Prof. Dr.    0241 / 80-89805   
Agirov Klinik Recruiting
Berg, Germany, 82335
Contact: Christian Straka, PD Dr. med.    +49-0815117806   
HELIOS Klinikum Berlin-Buch Recruiting
Berlin, Germany, 13125
Contact: Christian Gerecke, Dr. med.    +49-030 9401 12 190   
Evangelisches Krankenhaus Bielefeld Not yet recruiting
Bielefeld, Germany, 33611
Contact: Eva Bettina Zinngrebe, MD    05 21 / 772-75750   
Klinikum Bremen-Mitte Recruiting
Bremen, Germany, 28177
Contact: Bernd Hertenstein, Prof. Dr.    +49-421-4975240   
Universitätsklinik Erlangen Recruiting
Erlangen, Germany, 91054
Contact: Wolf Rösler, Dr. med.         
Contact    +49-9131-85 36991   
Universitätsklinikum Freiburg Recruiting
Freiburg, Germany, 79106
Contact: Monika Engelhardt, Prof. Dr.    +49-7 612 70 - 34 61   
Universitätsklinikum der Ernst-Moritz-Arndt-Universität Greifswald -Anstalt öffentlichen Rechts- Not yet recruiting
Greifswald, Germany, 17475
Contact: Gottfried Dölken, Prof. Dr.    03834-86-6698   
Universitätsklinikum Göttingen Recruiting
Göttingen, Germany, 37075
Contact: Wolfram Jung, Dr. med.    +49-551-39 8558   
Universitätsklinikum Hamburg-Eppendorf Recruiting
Hamburg, Germany, 20246
Contact: Georgia Schilling, Dr. med.    +49-40-741055692   
Asklepios Klinik Altona Recruiting
Hamburg, Germany, 22763
Contact: Hans Salwender, Dr. med.    +49-40- 181881-1211   
Universitätsklinikum Schleswig-Holstein Recruiting
Kiel, Germany, 24105
Contact: Martin Gramatzki, Prof. Dr.    0431-597 5802   
Stiftungsklinikum Mittelrhein gGmbH Recruiting
Koblenz, Germany, 56068
Contact: Ralph Naumann, Prof. Dr.   
Klinikum Landshut gemeinnützige GmbH Recruiting
Landshut, Germany, 84034
Contact: Juliana Ababei, Dr. med.    +49-871-698-0   
Stauferklinikum Schwäbisch Gmünd Recruiting
Mutlangen, Germany, 73557
Contact: Holger Hebart, Prof. Dr.    +49- 07171-701-1302   
Hämato-Onkologische Schwerpunktpraxis Not yet recruiting
München, Germany, 80331
Contact: Jochem Walther, Dr. med.    089554416   
Onkologische Praxis Elisenhof Recruiting
München, Germany, 80335
Contact: Peter Bojko, PD Dr. med.    +49-89- 452256-0   
Klinikum München Harlaching Recruiting
München, Germany, 81545
Contact: Marcus Hentrich, PD Dr. med.    089-62102663   
Klinikum rechts der Isar Recruiting
München, Germany, 81675
Contact: Tobias Dechow, PD Dr. med.    +49-89-4140 5834   
Klinikum Nord Recruiting
Nürnberg, Germany, 90419
Contact: Hannes Wandt, Prof. Dr.    +49-911-398 3650   
Klinikum Oldenburg Recruiting
Oldenburg, Germany, 26133
Contact: Bernd Metzner, Dr. med.    +49-441-403 72955   
Klinikum Ernst von Bergmann gGmbH Recruiting
Potsdam, Germany, 14467
Contact: Georg Maschmeyer, Prof. Dr.    0331-241-6001   
Gemeinschaftspraxis für Innere Medizin, Hämatologie und Onkologie Recruiting
Ravensburg, Germany, 88214
Contact: Thomas Decker, PD Dr. med.    +49 751/ 36650-35   
Klinikum der Universität Regensburg Recruiting
Regensburg, Germany, 93053
Contact: Albrecht Reichle, Prof. Dr.    +49-941-944 5541   
Diakonie-Klinikum Stuttgart-Diakonissenkrankenhaus und Paulinenhilfe gGmbH Recruiting
Stuttgart, Germany, 70176
Contact: Else Heidemann, Prof. Dr.    +49-711-991-3501   
Robert-Bosch-Krankenhaus Recruiting
Stuttgart, Germany, 70376
Contact: Martin Kaufmann, Dr. med.    0711-8101-3174   
Klinikum Traunstein Recruiting
Traunstein, Germany, 83278
Contact: Thomas W Kubin, Dr. med.    +49-861-705 1243   
Universitätsklinikum Ulm Recruiting
Ulm, Germany, 89081
Contact: Christian Langer, Dr. med.    +49-731-500-45743   
HSK Dr. Horst-Schmidt-Kliniken gmbh Recruiting
Wiesbaden, Germany, 65199
Contact: Norbert Frickhofen, Prof. Dr.    +49- 611-43-3009   
Universitätsklinikum Würzburg Recruiting
Würzburg, Germany, 97080
Contact: Stefan Knop, PD Dr. med.    +49-931-20170800   
Sponsors and Collaborators
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
ClinAssess GmbH
Layout table for investigator information
Principal Investigator: Christian Straka Agirov Klinik

Layout table for additonal information
Responsible Party: Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH Identifier: NCT01090089     History of Changes
Other Study ID Numbers: DSMM XIII
First Posted: March 19, 2010    Key Record Dates
Last Update Posted: September 8, 2017
Last Verified: September 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dexamethasone acetate
BB 1101
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents